Key regions: Japan, India, Italy, Brazil, South Korea
The demand for Anti-Hypertensive Drugs in G20 countries has been increasing steadily over the years due to various factors.
Customer preferences: Customers in G20 countries have been increasingly aware of the risks associated with hypertension and are therefore more inclined to purchase anti-hypertensive drugs. Additionally, the aging population in these countries has contributed to the growth of the market, as hypertension is more common in older individuals.
Trends in the market: In the United States, the market for anti-hypertensive drugs is driven by the high prevalence of hypertension and the availability of a wide range of drugs. In Japan, the market is growing due to the increasing number of elderly people and the high prevalence of hypertension. In China, the market is driven by the increasing urbanization and the adoption of a Western lifestyle, which has led to an increase in cases of hypertension. In India, the market is growing due to the high burden of hypertension and the increasing awareness about the condition.
Local special circumstances: In Brazil, the market for anti-hypertensive drugs is driven by the high prevalence of hypertension and the availability of affordable generic drugs. In Russia, the market is growing due to the increasing number of elderly people and the high prevalence of hypertension. In Saudi Arabia, the market is driven by the high prevalence of hypertension among the population and the increasing adoption of a sedentary lifestyle.
Underlying macroeconomic factors: The growth of the Anti-Hypertensive Drugs market in G20 countries can also be attributed to underlying macroeconomic factors. The increasing healthcare expenditure in these countries has led to greater access to healthcare services, including the availability of anti-hypertensive drugs. Additionally, the increasing disposable income in these countries has led to a greater ability to afford these drugs. Finally, the increasing urbanization in these countries has led to a greater awareness about the risks associated with hypertension and the need for anti-hypertensive drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
